Fleroxacin: in-vitro activity worldwide against 20,807 clinical isolates and comparison to ciprofloxacin and norfloxacin

Publisher Website
Google Scholar
Abstract
By June 1987 worldwide investigators from 37 centres in 12 countries had completed epidemiological susceptibility testing studies comparing the in-vitro activity of fleroxacin with that of ciprofloxacin, norfloxacin and other antibacterials. In this paper the results of these studies, expressed primarily as MIC90s, are reviewed and analysed for centre to centre variability. Twenty thousand eight hundred and seven strains were evaluable for comparative analysis. All three quinolones exhibited high in-vitro activity against Enterobacteriaceae (MIC90 ⩽0·125–2 mg/1), other common aerobic Gram-negative bacilli or coccobacilli (MIC90 ⩽0·125–1 mg/1) and staphylococci, including selected resistant isolates (MIC90 ⩽0·5–4 mg/1), and moderate to weak activity against streptococci and anaerobes (MIC90 = 1 –⩾8 mg/1). The activity of fleroxacin and norfloxacin was quite similar, but was usually inferior to that of ciprofloxacin. Comparison of data from the various investigating centres showed divergent results for many bacterial species, the MIC90s for the same quinolone varying by two to four dilution steps or more from centre to centre.

This publication has 0 references indexed in Scilit: